Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 6/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7361888 | 0.89 | TAAR1 (0.49) | TAAR1CYP2D6MAOAMAOBLMNA | |
| SCHEMBL9828265 | 0.88 | TAAR1 (0.67) | TAAR1CYP2D6ALDH1A1CALM1GAA | |
| SCHEMBL8225259 | 0.83 | CYP2D6 (0.50) | TAAR1CYP2D6MAOAMAOBLMNA | |
| SCHEMBL16606276 | 0.82 | TAAR1 (0.46) | TAAR1CYP2D6ALDH1A1CALM1HPGD | |
| SCHEMBL1253622 | 0.80 | TAAR1 (0.79) | TAAR1CYP2D6LMNAHTTALDH1A1 | |
| SCHEMBL28430686 | 0.80 | TAAR1 (0.56) | TAAR1CYP2D6LMNAHTTALDH1A1 | |
| SCHEMBL315045 | 0.80 | TAAR1 (0.52) | TAAR1CYP2D6MAOAMAOBLMNA | |
| SCHEMBL8255914 | 0.80 | TAAR1 (0.52) | TAAR1CYP2D6LMNAHTTALDH1A1 | |
| SCHEMBL3777135 | 0.80 | TAAR1 (0.52) | TAAR1CYP2D6LMNAHTTALDH1A1 | |
| SCHEMBL4081586 | 0.80 | TAAR1 (0.52) | TAAR1CYP2D6LMNAHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010104929-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | ELIXIR PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| US-7186730-B2 | Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-03-06 | — | — | US | disclosed |
| EP-1392686-B1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2006-10-18 | — | — | EP | disclosed |
| US-20040198755-A1 | Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-10-07 | — | — | US | disclosed |
| EP-1392686-A1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002096907-A1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198755-A1 | Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials | NRDC, NUCB2, ASNS | TAAR1 3593/4885CYP2D6 1230/4885MAOA 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.